株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

創傷:パイプラインレビュー

Wounds - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 255970
出版日 ページ情報 英文 236 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
創傷:パイプラインレビュー Wounds - Pipeline Review, H2 2015
出版日: 2015年11月30日 ページ情報: 英文 236 Pages
概要

創傷は、手術、怪我、化学薬品、熱や冷気への接触、摩擦、圧力、あるいは下肢潰瘍や癌など疾患の影響で、皮膚と皮下組織が傷つくことで起こる皮膚の保護機能の損傷(上皮細胞の連続性の損壊)であり、皮下接合組織(筋肉、骨、神経)の損傷を含む場合と含まない場合があります。傷の周辺が発赤あるいは赤い線状になり、幹部の腫れ、膿状の液体の分泌、悪臭、悪寒、発熱などの症状があります。抗生剤の利用などの治療法があります。

当レポートでは、世界における創傷治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

創傷の概要

治療薬の開発

  • 創傷向けパイプライン製品:概要
  • 創傷向けパイプライン製品:比較分析

創傷:開発中の治療薬:企業別

創傷:開発中の治療薬:大学・研究機関別

創傷:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階不明の製品

創傷:開発中の製品:企業別

創傷:開発中の製品:大学・研究機関別

創傷:治療薬開発に従事している企業

  • Cardium Therapeutics, Inc.
  • Smith & Nephew Plc
  • Sanofi
  • Biotec Pharmacon ASA
  • Kuros Biosurgery AG
  • Pharming Group N.V.
  • Stratatech Corporation
  • Photopharmica Limited
  • Tissue Repair Company
  • Nanotherapeutics, Inc.
  • Octapharma AG
  • Apricus Biosciences, Inc.
  • Bio3 Research S.r.l
  • NeoStem, Inc.
  • HanAll Biopharma Co., Ltd.
  • Sucampo Pharmaceuticals, Inc.
  • CytoTools AG
  • CYATHUS EXQUIRERE PharmaforschungsGmbH
  • MetrioPharm AG
  • Dongkook Pharmaceutical Co., Ltd.
  • Juventas Therapeutics, Inc.
  • Omnio Healer AB
  • ConjuGon, Inc.
  • Garnet BioTherapeutics
  • Gene Signal International SA
  • AndroScience Corporation
  • GliaMed, Inc.
  • Omeros Corporation
  • NanoBio Corporation
  • FirstString Research, Inc.
  • Molecular Design International, Inc.
  • Sirnaomics, Inc.
  • SunTen Phytotech Co., Ltd.
  • miRagen Therapeutics, Inc.
  • Pacific Northwest Biotechnology, LLC
  • Beech Tree Labs, Inc.
  • Mirrx Therapeutics A/S
  • EyeGene, Inc.
  • Neumedicines Inc.
  • AlgiPharma AS
  • SomaGenics Inc.
  • Advancell
  • Birken AG
  • Provasculon, Inc.
  • Pergamum AB
  • Microbion Corporation
  • Escape Therapeutics, Inc.
  • Kasiak Research Pvt. Ltd.
  • Regenics AS
  • vida therapeutics inc.
  • Hemostemix Ltd

創傷:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • MB-11316
  • ドキシサイクリン
  • GAM-501
  • DermaPro CL-05
  • GBT-009
  • HP-802247
  • StrataGraft皮膚組織
  • KUR-212
  • PPA-904
  • Granexin
  • CSTC-1
  • Evitar
  • JVS-100
  • 創傷治療のための間葉細胞
  • ビスマスエタンジチオール
  • MALP-2
  • KUR-213
  • GM-1485
  • CTR-2
  • cobiprostone
  • アルプロスタジル
  • ASCJ-9
  • MDI-301
  • GS-156
  • 可溶性ベータグルカン
  • MGN-4220
  • STP-705
  • BTL-slo
  • NB-201
  • 炎症、虚血症、創傷治癒のためのVEカドヘリン阻害RNAiオリゴヌクレオチド
  • NMIL-121
  • Vasculotide
  • AKB-4924
  • ニューロテンシン
  • C-31510
  • MP-1031
  • 皮膚病・感染症向けペプチド
  • CM-101
  • 慢性創傷・皮膚硬化症のための幹細胞治療
  • ANs-31
  • HL-156Fib
  • AlloGraf
  • GN-4474
  • HDFx
  • 創傷向けc-Met拮抗薬
  • EG-Decorin
  • 慢性傷感染向けビスマスチオール化合物
  • 創傷向け幹細胞治療
  • 急性創傷治療のための小分子
  • AG-30/5C
  • 組み換えプラスミノーゲン
  • Vernex
  • V-2248
  • 移動刺激因子
  • STD-06
  • 感染症、ショック、呼吸器障害のためのSEB・TSST-1阻害たんぱく質
  • NL-005
  • hVGF
  • PGF
  • 脱毛症、肺線維症、皮膚病向け成長因子ベータ受容体変形小分子アンタゴニスト
  • Nu-2
  • PRF-65339
  • A3-APO
  • BCI
  • コーディン
  • ヒト可溶性CD-146
  • フェニトイン
  • 塩化ピルビニウム
  • Cyathus-1102-B
  • 創傷治癒のための幹細胞治療
  • DNAプロドラッグプログラム
  • 炎症、やけど、創傷のためのモノクローナル抗体ゲル
  • 創傷・潰瘍のCA5-HIF遺伝子治療
  • 創傷治癒のための11s-HSD1阻害薬
  • 皮膚創傷のための脂肪幹細胞治療
  • 糖尿病性慢性皮膚創傷のための自己由来脂肪幹細胞治療
  • NVN-4428
  • I型組み換えヒトコラーゲン
  • 創傷・火傷のためのOligoG
  • 創傷治癒・新しい毛嚢形成のためのLGR6標的小分子
  • アジアチコシド誘導体
  • GP-505
  • 皮膚疾患・感染症向け酵素
  • 創傷の細胞治療
  • 線維芽細胞増殖因子結合体
  • PXL-181
  • 創傷治癒のためのRNAiオリゴヌクレオチド
  • 創傷治癒プログラム
  • 無糖線維芽細胞増殖因子
  • 中毒、代謝性疾患、筋骨格系疾患のためのNOシンターゼ阻害小分子
  • BCP-01
  • Refaheal
  • ヒト成長因子
  • 組換えプラスミノーゲン
  • XEN-103
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7310IDB

Summary

Global Markets Direct's, 'Wounds - Pipeline Review, H2 2015', provides an overview of the Wounds's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Wounds
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Wounds
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wounds Overview
  • Therapeutics Development
    • Pipeline Products for Wounds - Overview
    • Pipeline Products for Wounds - Comparative Analysis
  • Wounds - Therapeutics under Development by Companies
  • Wounds - Therapeutics under Investigation by Universities/Institutes
  • Wounds - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Wounds - Products under Development by Companies
  • Wounds - Products under Investigation by Universities/Institutes
  • Wounds - Companies Involved in Therapeutics Development
    • Advancell
    • Aerpio Therapeutics, Inc.
    • AlgiPharma AS
    • AndroScience Corporation
    • AnGes MG, Inc.
    • Aridis Pharmaceuticals LLC
    • Beech Tree Labs, Inc.
    • Berg LLC
    • Bio3 Research S.r.l
    • Biokine Therapeutics Ltd.
    • Biotec Pharmacon ASA
    • Birken AG
    • Blueberry Therapeutics Ltd
    • Caladrius Biosciences, Inc.
    • Cellphire, Inc.
    • CorMedix, Inc.
    • Destiny Pharma Limited
    • FibroGen, Inc.
    • Foresee Pharmaceuticals, LLC
    • GangaGen Inc.
    • Gene Signal International SA
    • GlaxoSmithKline Plc
    • HanAll Biopharma Co., Ltd.
    • IntelliCell BioSciences Inc.
    • Juventas Therapeutics, Inc.
    • Kuros Biosurgery AG
    • LegoChem Biosciences, Inc
    • Living Cell Technologies Limited
    • Molecular Design International, Inc.
    • NatureWise Biotech & Medicals Corporation
    • Novan, Inc.
    • Nuvo Research Inc.
    • Octapharma AG
    • Omeros Corporation
    • Pacific Northwest Biotechnology, LLC
    • ProMetic Life Sciences Inc.
    • Regenics AS
    • RXi Pharmaceuticals Corporation
    • Sanofi
    • SomaGenics Inc.
    • Stratatech Corporation
    • Sucampo Pharmaceuticals, Inc.
    • Symic Biomedical, Inc.
    • TGV-Laboratories
    • Thesan Pharmaceuticals, Inc.
    • TumorEnd, LLC
    • VBS Pharmaceuticals
    • Vida Therapeutics Inc.
  • Wounds - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-3APO - Drug Profile
    • Adipose Stem Cell Therapy for Skin Wound - Drug Profile
    • AG-30/5C - Drug Profile
    • AKB-4924 - Drug Profile
    • ALLO-ASC - Drug Profile
    • ANs-31 - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile
    • APO-2 - Drug Profile
    • AR-101 - Drug Profile
    • Arginine Butyrate - Drug Profile
    • ARN-077 - Drug Profile
    • ASCJ-9 - Drug Profile
    • Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound - Drug Profile
    • Autologous Vascular Cells Therapy - Drug Profile
    • BB-1000 - Drug Profile
    • Biosimilar for Diabetic Wounds - Drug Profile
    • BKT-170 - Drug Profile
    • BTL-slo - Drug Profile
    • CAR Peptide - Drug Profile
    • Cell Therapy for Dermatology and Immunology - Drug Profile
    • Cell Therapy for Wounds - Drug Profile
    • CM-101 - Drug Profile
    • cobiprostone - Drug Profile
    • CR-2016 - Drug Profile
    • CRMD-004 - Drug Profile
    • CTR-2 - Drug Profile
    • daprodustat - Drug Profile
    • DB-2121 - Drug Profile
    • Drug for Dermatology and Infectious Diseases - Drug Profile
    • Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile
    • Drugs to Activate iRhom2 for Wound Healing and Cancer - Drug Profile
    • Drugs to Agonize c-Met for Wounds - Drug Profile
    • Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile
    • FG-6874 - Drug Profile
    • FP-009 - Drug Profile
    • Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
    • GS-156 - Drug Profile
    • HL-156FIB - Drug Profile
    • Human Growth Factor - Drug Profile
    • hVGF - Drug Profile
    • JM-2 - Drug Profile
    • JVS-100 - Drug Profile
    • KL-7016 - Drug Profile
    • KUR-213 - Drug Profile
    • LCB-030110 - Drug Profile
    • LWnt-3a - Drug Profile
    • MDI-301 - Drug Profile
    • Mesenchymal Cells for Wound Care - Drug Profile
    • MG-53 - Drug Profile
    • MMP-26051 - Drug Profile
    • MMP-26052 - Drug Profile
    • Monoclonal Antibody Conjugated for Burns and Wounds - Drug Profile
    • Mul-1867 - Drug Profile
    • NBM-67 - Drug Profile
    • ND-336 - Drug Profile
    • NTCELL - Drug Profile
    • OleogelS-10 - Drug Profile
    • Oligomer G for Wounds And Burns - Drug Profile
    • Oxofoam - Drug Profile
    • P-128 - Drug Profile
    • Panaecin - Drug Profile
    • Pelladerm - Drug Profile
    • Peptide for Wounds - Drug Profile
    • perflenapent for wound healing - Drug Profile
    • Perlecan - Drug Profile
    • PGF - Drug Profile
    • plasminogen (recombinant) - Drug Profile
    • Polysaccharide for Wounds and Scars - Drug Profile
    • Protein for Diabetic Wound Healing - Drug Profile
    • Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile
    • Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile
    • Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
    • Protein to Inhibit SEB and TSST-1 for Infectious Disease, Dermatology, Respiratory Disorders and Other Diseases - Drug Profile
    • Recombinant Erythropoetin For Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
    • Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile
    • Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
    • RNAi Oligonucleotide for Wound Healing - Drug Profile
    • Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles - Drug Profile
    • Small Molecules for Wounds and Scars - Drug Profile
    • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
    • Soluble Beta Glucan - Drug Profile
    • Stem Cell Therapy for Wound Healing - Drug Profile
    • Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
    • Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds - Drug Profile
    • Synthetic Peptides to Activate VEGF for Wound Healing and Neurodegenerative Diseases - Drug Profile
    • Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
    • Thrombosomes - Drug Profile
    • TRT-8174 - Drug Profile
    • ubidecarenone - Drug Profile
    • V-2248 - Drug Profile
    • Vernex - Drug Profile
    • VRP-017 - Drug Profile
    • VTI-3000 Series - Drug Profile
    • XF-70 - Drug Profile
  • Wounds - Recent Pipeline Updates
  • Wounds - Dormant Projects
  • Wounds - Discontinued Products
  • Wounds - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wounds, H2 2015
  • Number of Products under Development for Wounds - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Wounds - Pipeline by Advancell, H2 2015
  • Wounds - Pipeline by Aerpio Therapeutics, Inc., H2 2015
  • Wounds - Pipeline by AlgiPharma AS, H2 2015
  • Wounds - Pipeline by AndroScience Corporation, H2 2015
  • Wounds - Pipeline by AnGes MG, Inc., H2 2015
  • Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2015
  • Wounds - Pipeline by Beech Tree Labs, Inc., H2 2015
  • Wounds - Pipeline by Berg LLC, H2 2015
  • Wounds - Pipeline by Bio3 Research S.r.l, H2 2015
  • Wounds - Pipeline by Biokine Therapeutics Ltd., H2 2015
  • Wounds - Pipeline by Biotec Pharmacon ASA, H2 2015
  • Wounds - Pipeline by Birken AG, H2 2015
  • Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2015
  • Wounds - Pipeline by Caladrius Biosciences, Inc. , H2 2015
  • Wounds - Pipeline by Cellphire, Inc., H2 2015
  • Wounds - Pipeline by CorMedix, Inc., H2 2015
  • Wounds - Pipeline by Destiny Pharma Limited, H2 2015
  • Wounds - Pipeline by FibroGen, Inc., H2 2015
  • Wounds - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
  • Wounds - Pipeline by GangaGen Inc., H2 2015
  • Wounds - Pipeline by Gene Signal International SA, H2 2015
  • Wounds - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Wounds - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Wounds - Pipeline by IntelliCell BioSciences Inc., H2 2015
  • Wounds - Pipeline by Juventas Therapeutics, Inc., H2 2015
  • Wounds - Pipeline by Kuros Biosurgery AG, H2 2015
  • Wounds - Pipeline by LegoChem Biosciences, Inc, H2 2015
  • Wounds - Pipeline by Living Cell Technologies Limited, H2 2015
  • Wounds - Pipeline by Molecular Design International, Inc., H2 2015
  • Wounds - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015
  • Wounds - Pipeline by Novan, Inc., H2 2015
  • Wounds - Pipeline by Nuvo Research Inc., H2 2015
  • Wounds - Pipeline by Octapharma AG, H2 2015
  • Wounds - Pipeline by Omeros Corporation, H2 2015
  • Wounds - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015
  • Wounds - Pipeline by ProMetic Life Sciences Inc., H2 2015
  • Wounds - Pipeline by Regenics AS, H2 2015
  • Wounds - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
  • Wounds - Pipeline by Sanofi, H2 2015
  • Wounds - Pipeline by SomaGenics Inc., H2 2015
  • Wounds - Pipeline by Stratatech Corporation, H2 2015
  • Wounds - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
  • Wounds - Pipeline by Symic Biomedical, Inc., H2 2015
  • Wounds - Pipeline by TGV-Laboratories, H2 2015
  • Wounds - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015
  • Wounds - Pipeline by TumorEnd, LLC, H2 2015
  • Wounds - Pipeline by VBS Pharmaceuticals, H2 2015
  • Wounds - Pipeline by Vida Therapeutics Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Wounds Therapeutics - Recent Pipeline Updates, H2 2015
  • Wounds - Dormant Projects, H2 2015
  • Wounds - Dormant Projects (Contd..1), H2 2015
  • Wounds - Dormant Projects (Contd..2), H2 2015
  • Wounds - Dormant Projects (Contd..3), H2 2015
  • Wounds - Dormant Projects (Contd..4), H2 2015
  • Wounds - Dormant Projects (Contd..5), H2 2015
  • Wounds - Dormant Projects (Contd..6), H2 2015
  • Wounds - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Wounds, H2 2015
  • Number of Products under Development for Wounds - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top